Walliser P, Benzie C R, Kay J E
Biochemistry Laboratory, School of Biological Sciences, University of Sussex, Brighton.
Immunology. 1989 Nov;68(3):434-5.
The novel immunosuppressive drug FK-506 inhibits both cell-mediated and humoral immunity in vivo and suppresses T-lymphocyte activation at nanamolar concentrations in vitro. We report here that FK-506 also inhibits the in vitro proliferation of murine B lymphocytes induced by goat antimouse IgM (GaMIgM), although it does not affect the induction of proliferation by bacterial lipopolysaccharide (LPS). The action of FK-506 on B-lymphocyte proliferation thus resembles that of cyclosporin A, further strengthening the correlation between the action of the two immunosuppressive drugs previously reported for T-lymphocyte activation.
新型免疫抑制药物FK-506在体内可抑制细胞介导的免疫和体液免疫,并在体外以纳摩尔浓度抑制T淋巴细胞活化。我们在此报告,FK-506也可抑制山羊抗小鼠IgM(GaMIgM)诱导的小鼠B淋巴细胞的体外增殖,尽管它不影响细菌脂多糖(LPS)诱导的增殖。因此,FK-506对B淋巴细胞增殖的作用类似于环孢素A,进一步加强了先前报道的这两种免疫抑制药物对T淋巴细胞活化作用之间的相关性。